#USA #New York #Class Action #Levi & Korsinsky #aTyr Pharma

aTyr Pharma Investors Alerted by Levi & Korsinsky

Levi & Korsinsky, LLP is warning investors of aTyr Pharma, Inc. (NASDAQ: ATYR) about a class action lawsuit concerning alleged securities fraud. This notification comes as the firm aims to represent individuals who incurred losses due to misleading statements made by the company during a critical period from November 7, 2024, to September 12, 2025. The firm is encouraging affected investors to take action before the approaching deadline of December 8, 2025.

Class Action Overview

The lawsuit aims to recover losses for aTyr's investors who were adversely affected by claims of fraud on the securities market. Allegations suggest that during the specified time frame, aTyr Pharma misled its stakeholders with overly positive statements, despite concealing significant adverse facts about the efficacy of its drug, Efzofitimod. Notably, it was claimed that the drug would enable patients to fully taper their steroid treatment, a statement that was later proven false.

On September 15, 2025, the company disclosed that its EFZO-FIT study did not meet the primary endpoint, revealing the truth about the misrepresented capabilities of the drug. This disclosure caused a drastic decrease in the company's stock price, plummeting from $6.03 to $1.02 per share, a staggering 83.2% drop in just one day.

What Should Investors Do?

If you suffered financial losses related to aTyr, it’s crucial to consider joining the class action suit. Levi & Korsinsky has a strong reputation, having secured hundreds of millions in compensation for investors over the past two decades. Interested persons can fill out a submission form on their website or get in touch directly via phone at (212) 363-7500 to seek guidance on the next steps without incurring any costs or obligations.

No Financial Burden for Class Members

Participating in this class action lawsuit incurs no fees for class members, as recovery does not require any upfront costs. This fact makes it essential for impacted investors to act promptly to ensure their inclusion in the proceedings. Furthermore, eligibility for potential recovery doesn’t hinge on whether one chooses to be a lead plaintiff in the case.

Levi & Korsinsky’s Expertise

Levi & Korsinsky has established itself as a leader in securities litigation, with their attorneys highly skilled at navigating complex legal landscapes. The firm boasts a dedicated team of over 70 professionals, ensuring that clients receive top-tier service and representation. With a consistent ranking in the ISS Securities Class Action Services’ Top 50 Report, their credibility is well recognized in the industry.

Contact Information

For more details on the case, interested parties can reach out to the law firm at:

• - Address: 33 Whitehall Street, 27th Floor, New York, NY 10004
• - Email: [email protected]
• - Phone: (212) 363-7500

In conclusion, investors who have suffered losses from aTyr Pharma are urged to reach out and explore their options, ensuring they do not miss out on potential recovery opportunities.